Mitochondrial & Metabolic

AOD-9604 (Modified hGH C-Terminal Fragment)

For Research Use Only. Not for Human or Veterinary Use.

Overview

AOD-9604 is a synthetic peptide based on the C-terminal fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine and a stabilising disulfide bond. In preclinical research it is studied for stimulating fat breakdown (lipolysis) and reducing fat formation (lipogenesis) in adipose tissue — reportedly without the glucose or IGF-1 effects of full-length growth hormone. It is a research compound.

Chemical Profile

PropertyValue
CAS number221231-10-3
ClassModified hGH C-terminal fragment (Tyr + hGH 177–191)
Amino-acid sequenceH-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH
One-letter codeYLRIVQCRSVEGSCGF (16 aa)
Disulfide bondIntramolecular (Cys7–Cys14)
Molecular weight≈ 1815.1 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
AOD-9604 at a glance
Class
Modified hGH C-terminal fragment
Origin
Human growth hormone, residues 177–191 (+ Tyr)
Research status
Preclinical; early clinical (obesity)
Study route
Subcutaneous
Half-life
≈ 2–4 h
Key feature
Lipolytic without GH / IGF-1 axis effects

Mechanism of Action

AOD-9604 corresponds to the part of growth hormone associated with its fat-metabolising activity, separated from the parts that drive growth. It is studied for acting on adipocyte metabolism — promoting lipolysis and suppressing lipogenesis — reportedly without meaningfully activating the growth-hormone receptor or raising IGF-1, which is the property that distinguishes it from full-length hGH.

ComponentDetail
LipolysisStudied for activating hormone-sensitive lipase via cAMP/PKA
LipogenesisAssociated with downregulation of ACC and fatty-acid synthase
cAMPIncreased intracellular cAMP in adipocytes
GH receptorMinimal direct activation (no growth-promoting signal)
IGF-1Does not stimulate hepatic IGF-1 production
GlucoseNo effect on blood glucose in reported models
SystemStudied effect
Adipose tissueIncreased lipolysis, reduced fat accumulation
CartilageEnhanced proteoglycan synthesis in chondrocytes
Systemic metabolismNo effect on glucose or IGF-1 (selective peripheral action)

Pharmacology

ParameterValue
Half-life (t½)≈ 2–4 h
Bioavailability (SC)≈ 60–80% (estimated)
Tmax≈ 30–60 min (SC)
Protein bindingModerate
MetabolismProteolytic degradation
Route of administrationSubcutaneous (research)
EliminationRenal (peptide fragments)

Research Evidence

AOD-9604 has adipocyte and rodent research plus some early clinical work in obesity. Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

ModelResearch focusReference
Human adipocytes (in vitro)Lipolysis without GH-receptor activationNg FM, et al.
Rodent adipocyte cultureGlycerol release (lipolysis)Heffernan M, et al.
Diet-induced obese miceBody-fat reductionAOD-9604 preclinical literature
Chondrocyte cultureProteoglycan synthesisAOD-9604 preclinical literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Stimulated lipolysis without GH-receptor activationhuman adipocytesNg FM et al.
Reduced body fat without glucose or IGF-1 effectsdiet-induced obese micepreclinical literature
Enhanced chondrocyte proteoglycan synthesiscartilage culturespreclinical literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 300–1000 µg daily (SC), in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Final concentration≈ 2.5–5 mg/mL
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~7 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityMild injection-site reactions
GIWell tolerated in reported studies
Glucose / IGF-1No reported effect on blood glucose or IGF-1
CytotoxicityNo cytotoxicity observed
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble (> 20 mg/mL)
logP (octanol/water)≈ −1.8 (hydrophilic)
Structural featureOne intramolecular disulfide bond (two cysteines)
pH (reconstituted)5.0–6.5
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

AOD-9604 is made by Fmoc solid-phase synthesis, followed by controlled oxidative folding to form the single disulfide bond between its two cysteines — the folding step is what needs the most control to give a single defined product.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinWang or Rink resin
CouplingHBTU / HOBt with DIPEA
CleavageTFA / TIPS / H₂O with thiol scavengers
Disulfide formationControlled oxidative folding (Cys7–Cys14)
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Confirm the intramolecular disulfide bond (no free thiol by Ellman’s test / MS).

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, reversed-phase TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / massconsistent with the disulfide-bonded peptide
MALDI-TOFMass confirmationconsistent with the disulfide-bonded peptide
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode (consistent with the disulfide-bonded peptide). Confirm the intramolecular disulfide bond (no free thiol by Ellman’s test / MS).

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Confirm the intramolecular disulfide bond (no free thiol by Ellman’s test / MS).

Selected References

  • Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD-9604) of human growth hormone. Molecular and Cellular Endocrinology.
  • Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology / Life Sciences.
  • AOD-9604 preclinical and early-clinical obesity literature.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; disulfide confirmed
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need AOD-9604 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote